That was based on the phase III LIBERTY-AFRS-AIMS trial findings from 62 adults and kids with allergic fungal rhinosinusitis ...
GSK’s Exdensur receives China NMPA approval for the treatment of chronic rhinosinusitis with nasal polyps: London, UK Thursday, April 9, 2026, 09:00 Hrs [IST] GSK plc announced ...
Exdensur was approved in China as the first and only ultra-long-acting biologic for adult patients suffering from chronic rhinosinusitis with nasal polyps, according to a Wednesday filing. The disease ...
Caneil Satchwell has been named the 2026 Youth of the Year for the Boys and Girls Clubs of Greater Tampa Bay due to his years of leadership, community service and academic success. This is the second ...
GSK (LSE:GSK) has received Chinese regulatory approval for Exdensur (depemokimab) as the first ultra long acting biologic for ...
Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, ...
Depemokimab substantially reduced asthma exacerbations and improved respiratory quality of life and asthma control scores in patients with type 2 asthma and comorbid chronic rhinosinusitis with nasal ...
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study ...
Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic ...
The approval of depemokinab, of which Exdensur is the brand name, for chronic rhinosinusitis in addition to intranasal ...
For many residents in Centennial Hills, Summerlin, Skye Canyon, Providence and Northwest Las Vegas, those environmental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results